Skip to main content
. 2022 Feb 28;11(3):319. doi: 10.3390/antibiotics11030319

Figure 3.

Figure 3

Antimicrobial activity of Pro-D-BMAP18 in 25% (v/v) CF sputum in SCFM + 300 mM NaCl. CFU/mL count of (A) P. aeruginosa RP73 and (B) C. albicans SC5314 after 4 h incubation with Pro-D-BMAP18 (64 μg/mL), D-BMAP18 (64 μg/mL), tobramycin (8 μg/mL), and amphotericin B (1 μg/mL). Pro-D-BMAP18 (64 μg/mL) in heat-inactivated sputum was used as a negative control for enzymatic activity. Results are from three separate experiments in internal duplicate (n = 6). * = p < 0.05; ** = p < 0.01. A Student’s t-test of the treatments vs the untreated control is indicated.